SCHEMBL26467442

SCHEMBL26467442

C(/C=C/c1nc2ccccc2s1)=C\c1cccnc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.49
NPC1 O15118 7/20 0.49
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
MAPT P10636 7/20 0.47
MEN1 O00255 6/20 0.47
KMT2A Q03164 6/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
APP P05067 1/20 0.47
INSR P06213 1/20 0.47
NCOA1 Q15788 1/20 0.47
TDP1 Q9NUW8 1/20 0.46
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KDM4E B2RXH2 4/20 0.43
GAA P10253 2/20 0.43
ALDH1A1 P00352 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22359861 0.91 MEN1 (0.56) RAB9ANPC1CYP11B1CYP11B2MAPT
SCHEMBL26467465 0.85 MAPT (0.49) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL26467451 0.85 MAPT (0.57) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL11776645 0.85 MAPT (0.57) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL26467491 0.84 MAPT (0.54) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL22906792 0.80 RAB9A (0.51) RAB9ACYP11B1CYP11B2APPCYP1A2
SCHEMBL26467455 0.79 RAB9A (0.45) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL21889377 0.77 MEN1 (0.56) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL30434981 0.77 MEN1 (0.56) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL26094294 0.75 MEN1 (0.66) RAB9ANPC1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230133538-A1 TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-05-04 US disclosed
US-20230133538-A1 TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230133538-A1 TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 MAPT, PSEN1, PSEN2 RAB9A 1002/4885NPC1 2129/4885CYP11B1 4165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.